Thrombophilia as a multigenic disease

Haematologica

Volumn 84, Issue 1, 1999, Pages 59-70

  Zöller, Bengt ^a,b   De Frutos, Pablo García ^a   Hillarp, Andreas ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antithrombin; APC resistance; Factor V; Protein C; Protein S; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; POINT MUTATION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

3' UNTRANSLATED REGIONS; ACTIVATED PROTEIN C RESISTANCE; ADULT; AMINO ACID SUBSTITUTION; ANTITHROMBINS; CASE MANAGEMENT; CHILD; FACTOR V; FACTOR V DEFICIENCY; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT, NEWBORN; MALE; MUTATION, MISSENSE; PHENOTYPE; POINT MUTATION; PREVALENCE; PROTEIN C DEFICIENCY; PROTHROMBIN; RISK FACTORS; SCANDINAVIA; THROMBOPHILIA; THROMBOPHLEBITIS;

EID: 0344678336     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Egeberg O. On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on antithrombin deficient blood. Thromb Diath Haemorrh 1965; 14:473-89.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-8.
3. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anti coagulant protein C pathway defective in majority of thrombophilic patients . Blood 1993; 82:1989-93.
4. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
5. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
6. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91:1396-400.
7. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-7.
8. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V . Lancet 1994; 343:1535-6.
9. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
10. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343:1536-8.
11. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94:2521-4.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-703.
13. Carrell RW, Pemberton PA, Boswell DR. The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harb Symp Quant Biol 1987; 52:527-35.
14. Lawrence DA. The serpin-proteinase complex revealed. Nat Struct Biol 1997; 4:339-41.
15. Olson ST, Bjork I. Role of protein conformational changes, surface approximation and protein cofactors in heparin-accelerated antithrombin-proteinase reactions. Adv Exp Med Biol 1992; 313:155-65.
16. Olson ST, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J Biol Chem 1991; 266:6353-64.
17. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267:12528-38.
18. van Boeckel CA, Grootenhuis PD, Visser A. A mechanism for heparin-induced potentiation of antithrombin III . Nat Struct Biol 1994; 1:423-5.
19. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1-43.
20. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261:12022-7.
21. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269:18735-8.
22. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemostasis 1996; 76:208-14.
23. Varadi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII . Thromb Haemost 1995; 73:730-1.
24. Shen L, He X, Dahlbäck B. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex - species specific interactions of components of the protein C anticoagulant system. Thromb Haemostas 1997; 78:1030-6.
25. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87:4708-17.
26. Dahlbäck B. Factor V and protein S as cofactors to activated protein C. Haematologica 1997; 82:91-5.
27. Manotti C, Quintavalla R, Pini M, Jeran M, Paolicelli M, Dettori AG. Thromboembolic manifestations and congenital factor V deficiency: a family study. Haemostasis 1989; 19:331-4.
28. Egan JO, Kalafatis M, Mann KG. The effect of Arg306→Ala and Arg506→Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 1997; 6: 2016-27.
29. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270:21158-66.
30. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996; 313:467-72.
31. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270:4053-7.
32. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269:31869-80.
33. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85:3405-11.
34. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270:27852-8.
35. Zöller B, Holm J, Svensson P, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemostas 1996; 75:270-4.
36. Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemostas 1996; 75:703-5.
37. Simioni P, Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92:435-41.
38. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271:22949-52.
39. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-84.
40. Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism . Lancet 1996; 347:1374-5.
41. Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemostasis 1996; 76:510-3.
42. Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemostasis 1997; 77:440-3.
43. Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemostas 1997; 77:1219.
44. Simioni P, Girolami A. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagul Fibrinol 1994; 5:825-7.
45. Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemostas 1996; 75:422-6.
46. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90:1552-7.
47. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemostas 1996; 75:45-8.
48. Williamsson D, Brown K, Luddington R, Baglin C, Baglin T. A new mutation (Arg306Thr) associated with resistance to activated protein C. Blood 1998; 91:1140-4.
49. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91:1135-9.
50. Hillarp A, Dahlbäck B, Zöller B. Activated protein C resistance: from phenotype to genotype and clinical practice. Blood Rev 1995; 9:201-12.
51. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
52. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-8.
53. 52a. Ridker PM, Hennekens CH, Lindpaintner K, Stampfler MJ, Eisenberg PR, Miletich JP. Mutation in the gene for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. Lancet 1998; 351:88-92.
54. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemostas 1997; 77: 332-5.
55. Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997; 241:379-85.
56. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. N Engl J Med 1994; 331:1559-62.
57. Samama MM, Trossaert M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 86:4700-2.
58. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 1996; 95:579-86.
59. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-4.
60. Pepe C, Rickards O, Vanegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemostas 1997; 77:329-31.
61. Zöller B, Hillarp A, Berntorp E, Dahlbäck B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997; 48:45-58.
62. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89:397-402.
63. Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti C, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplo-type underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemostas 1997; 78:1037-41.
64. Lindqvist PC, Svensson PJ, Dahlbäck B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemostas 1998; 79:69-73.
65. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemostas 1998; 79:706-8.
66. Arruda VR, Annichino Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemostas 1997; 78:1430-3.
67. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997; 98:907-9.
68. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997; 17:2418-22.
69. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haernostas 1997; 78:990-2.
70. Aiach M, Borgel D, Gaussem P, Emmerich J, Alhenc Gelas M, Gandrille S. Protein C and protein S deficiencies. Semin Hematol 1997; 34:205-16.
71. Reitsma PH. Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res 1996; 24:157-9.
72. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemostas 1995; 73: 876-89.
73. Gandrille S, Borgel D, Ireland H, et al. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemostas 1997; 77:1201-14.
74. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemostas 1996; 76:651-62.
75. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemostas 1996; 76:824-34.
76. Simmonds RE, Ireland H, Lane DA, Zöller B, García de Frutos P, Dahlbäck B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128: 8-14.
77. Simmonds RE, Zöller B, Ireland H, et al. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89:4364-70.
78. Zöller B, García de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85:3524-31.
79. nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemostas 1997; 77:197-211.
80. Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. Thromb Haemostas 1997; 78:339-43.
81. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72:477-80.
82. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-5.
83. Hallam PJ, Millar DS, Krawczak M, Kakkar W, Cooper DN. Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. J Med Genet 1995; 32:543-5.
84. Gandrille S, Greengard JS, Alhenc Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor Vin 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood 1995; 86: 219-24.
85. McColl M, Tait RC, Walker ID, Perry DJ, McCall F, Conkie JA. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinol 1996; 7:689-94.
86. Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemostas 1995; 73:743-5.
87. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-23.
88. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemostas 1996; 75:417-21.
89. Alhenc Gelas M, Le Cam Duchez V, Emmerich J, et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families. Blood 1997; 90: 1711.
90. Howard TE, Marusa M, Boisza J, et al. The prothrombin gene 3′-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood 1998; 91:1092.
91. Zöller B, Svensson PJ, Dahlbäck B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood 1998; 91:2210-1.
92. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemostas 1997; 78: 1426-9.
93. Ehrenforth S, Ludwig G, Klinke S, Krause M, Scharrer I, Nowak-Göttl U. The prothrombin 20210A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrmbophilia. Blood 1998; 91:2209-10.
94. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptives and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177:887-91.
95. Organization WH. Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346:1582-8.
96. Organization WH. Collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346:1582-8.
97. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233-8.
98. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173:210-3.
99. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
100. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346:1593-6.
101. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93:487-90.
102. Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemostas 1997; 78:1480-3.
103. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955-60.
104. De Stefano V, Mastrangelo S, Paciaroni K, et al. Thrombotic risk during pregnancy and puerperium in women with APC-resistance - effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemostas 1995; 74:793-4.
105. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176:889-93.
106. Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92:473-8.
107. McColl MD, Ramsay JE,Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemostas 1997; 78:1183-8.
108. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ and Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome . N Engl J Med 1995; 332:993-7.
109. Fijnheer R, Horbach DA, Donders RC, et al. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemostas 1996; 76:514-7.
110. Davies KA, Ireland H, Athanassiou P, Loizou S, Lane D, Walport MJ. Factor V Leiden mutation and venous thrombosis. Lancet 1995; 345:132-3.
111. Bengtsson A, Zöller B, García de Frutos P, Dahlbäck B, Sturfelt G. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Lupus 1996; 5:598-601.
112. Sasso EH, Suzuki LA, Thompson AR, Petri MA. Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis Rheum 1997; 40:1720-1.
113. Dizon Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Hamostas 1995; 74:1029-31.
114. Lang IM, Klepetko W, Pabinger I. No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH) . Thromb Haemostas 1996; 76:476-7.
115. Zöller B, García de Frutos P, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemostas 1998; 79:802-7.
116. Sifontes MT, Nuss R, Jacobson LJ, Griffin JH, Manco Johnson MJ. Thrombosis in otherwise well children with the factor V Leiden mutation. J Pediatr 1996; 128:324-8.
117. Kodish E, Potter C, Kirschbaum NE, Foster PA. Activated protein C resistance in a neonate with venous thrombosis. J Pediatr 1995; 127:645-8.
118. Gurgey A, Mesci L, Renda Y, Olcay L, Kocak N, Erdem G. Factor V Q 506 mutation in children with thrombosis. Am J Hematol 1996; 53:37-9.
119. Nowak-Göttl U, Koch HG, Aschka I, et al. Resistance to activated protein C (APCR) in children with venous or aarterial thromboembolism. Br J Haematol 1996; 92:992-8.
120. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol 1997; 34:171-87.
121. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemostas 1995; 74:94-100.